(Q35601634)

9 August 2017

1 reference

title

Adjuvant therapy for older women with breast cancer (English)

1 reference

9 August 2017

Muss HB

1

1 reference

9 August 2017

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

12

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

550-557

1 reference

9 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Comorbidity and functional status are independent in older cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

The effect of comorbidity on 3-year survival of women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Estimating treatment benefits for the elderly: the effect of competing risks

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

What threshold for adjuvant therapy in older breast cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Representation of older patients in cancer treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Referral of breast cancer patients to medical oncologists after initial surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900165-6

7 January 2021

10.1016/S0960-9776(03)00165-6

Identifiers

DOI

1 reference

9 August 2017

1 reference